Skip to main
  1. Stocks
  2. NRX Pharmaceuticals
  3. Forecast
NRXP

NRX Pharmaceuticals (NRXP) Stock Forecast & Price Target

NRX Pharmaceuticals (NRXP) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NRX Pharmaceuticals is positioned favorably because it has already transitioned from a clinical story to a commercial one with KETAFREE approved ahead of schedule, a 17-person sales force covering 80% of the ketamine market, and launch stock of about 5 million units with capacity for 1 million units per month. Its pipeline also looks de-risked by existing clinical data: NRX-100 and NRX-101 are based on known molecules, while NRX-101 has shown a greater-than-two-fold response improvement and an eight-fold remission increase versus TMS alone, with 87% response and 72% remission at six weeks in real-world data. The opportunity is amplified by large, underserved markets and near-term catalysts, including a $400M U.S. ketamine market, an $11.2M DARPA contract, and potential 2026/2027 FDA actions for NRX-100 and NRX-101 in bipolar depression with suicidality.

Bears say

NRX Pharmaceuticals is a clinical-stage company whose Q2 2026 results underscored weak commercial traction, with revenue of only $1.1 million versus estimates of $3.0–16.6 million and no company guidance to anchor expectations. The business also posted a wide net loss of $16.5 million, or $(0.44) per share, highlighting continued heavy cash burn and a development model that remains dependent on uncertain future clinical and regulatory progress rather than durable sales. Although the HOPE business began generating revenue in Q3 2025, the scale remains too small to offset the company’s losses, leaving the stock exposed to financing risk and execution uncertainty.

NRX Pharmaceuticals (NRXP) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NRX Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

NRX Pharmaceuticals (NRXP) Analyst Forecast & Price Prediction

Get the latest NRX Pharmaceuticals (NRXP) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in NRX Pharmaceuticals (NRXP)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NRX Pharmaceuticals (NRXP) Forecast

Analysts have given NRX Pharmaceuticals (NRXP) a Strong Buy based on their latest research and market trends.

According to 4 analysts, NRX Pharmaceuticals (NRXP) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NRX Pharmaceuticals (NRXP)


NRX Pharmaceuticals (NRXP) Analyst Forecast & Price Prediction

Get the latest NRX Pharmaceuticals (NRXP) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in NRX Pharmaceuticals (NRXP)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NRXP stock data and trends